Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (MAZE) Revenue
Annual & quarterly revenue history · segment & region breakdown
MAZE · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsMaze Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.02B, a decrease of 100.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2022 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.17B | -100.00% |
| 2024-12-31 | $0.17B | +$0.17B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare MAZE revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Maze Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Maze Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Maze Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MAZE revenue · 4 questionsMAZE's trailing twelve-month (TTM) revenue is $0.02B. That is a decrease of 100.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Maze Therapeutics, Inc. SEC filings · GAAP · Maze Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026